What is Erste Group Bank's Estimate for MRK FY2027 Earnings?

Key Points

• Erste Group Bank slightly raised its FY2027 EPS estimate for Merck to $9.67 from $9.66, indicating a modestly more optimistic long-term outlook.
• The updated FY2027 estimate is far above the current full-year consensus EPS of $5.18, highlighting expectations for significant earnings growth over the next few years.
• Other analysts remain broadly positive on Merck, with several firms lifting price targets and the stock carrying an overall “Moderate Buy” rating and average target price of $131.83.

Merck & Co., Inc. (NYSE:MRK - Free Report) - Analysts at Erste Group Bank lifted their FY2027 earnings per share estimates for Merck & Co., Inc. in a research report issued to clients and investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $9.67 per share for the year, up from their prior estimate of $9.66. The consensus estimate for Merck & Co., Inc.'s current full-year earnings is $5.18 per share.

A number of other equities analysts also recently commented on the stock. CICC Research began coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price objective for the company. Wells Fargo & Company decreased their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating on the stock in a research report on Friday, May 1st. JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research note on Monday, April 6th. Scotiabank increased their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a research report on Tuesday. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $131.83.

Merck & Co., Inc. Stock Down 0.7%

MRK opened at $128.41 on Wednesday. The company has a market capitalization of $317.15 billion, a P/E ratio of 36.17, a P/E/G ratio of 2.90 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm's fifty day moving average price is $116.54 and its two-hundred day moving average price is $114.88. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $130.29.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.'s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Institutional Investors Weigh In On Merck & Co., Inc.

Large investors have recently made changes to their positions in the company. VectorGlobal IAG Inc. bought a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $900,000. Basecamp Wealth Advisors LLC increased its holdings in Merck & Co., Inc. by 1.7% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 8,202 shares of the company's stock valued at $987,000 after purchasing an additional 136 shares in the last quarter. Ballast Advisors LLC bought a new position in Merck & Co., Inc. in the 1st quarter valued at $196,000. Sapient Capital LLC grew its holdings in shares of Merck & Co., Inc. by 63.4% during the first quarter. Sapient Capital LLC now owns 16,402 shares of the company's stock worth $1,987,000 after purchasing an additional 6,365 shares during the last quarter. Finally, Vilga Financial Planning LLC bought a new stake in shares of Merck & Co., Inc. during the first quarter worth $232,000. Institutional investors own 76.07% of the company's stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Bank of America raised its price target on Merck to $141 from $130 and reiterated a buy rating, while Scotiabank lifted its target to $155 from $136 with a sector outperform view, signaling stronger Wall Street confidence in the stock’s upside. Bank of America and Scotiabank raise Merck price targets
• Positive Sentiment: Analysts also highlighted Merck’s lung cancer drug pipeline, saying an upcoming phase 3 readout for OptiTrop-Lung06 could improve the commercial outlook for SAC-TMT and boost future sales potential. Merck's Lung Cancer Drug Seen Boosting Sales Potential, BofA Says
• Positive Sentiment: Merck announced an agreement with the ADAP Crisis Task Force to improve access to HIV treatment through state programs, which may modestly support sentiment around its infectious-disease franchise. Merck Announces New Agreement with ADAP Crisis Task Force
• Neutral Sentiment: Broader healthcare stocks were softer late Tuesday, which may have added some pressure even as Merck continued to attract company-specific buying interest. Sector Update: Healthcare Stocks Softer Late Afternoon
• Negative Sentiment: Merck is also facing a bipartisan U.S. House investigation into whether clinical trials conducted in China, including at military-linked hospitals and in Xinjiang, raised national security or data-protection concerns, which could weigh on sentiment if the probe escalates. Merck (MRK) Faces U.S. Security Probe Over China Clinical Trials

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.